about
Vascular Remodelling and Mesenchymal Transition in Systemic SclerosisApplication of 2-dimensional difference gel electrophoresis (2D-DIGE) to the study of thrombin-activated human platelet secretome.Tissue Factor Expressed by Neutrophils: Another Piece in the Vascular Inflammation Puzzle.An intense and short-lasting burst of neutrophil activation differentiates early acute myocardial infarction from systemic inflammatory syndromesIntravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.Reduction of circulating neutrophils precedes and accompanies type 1 diabetesTranslational mini-review series on immunology of vascular disease: mechanisms of vascular inflammation and remodelling in systemic vasculitis.Platelet-leukocyte deregulated interactions foster sterile inflammation and tissue damage in immune-mediated vessel diseases.Instructive influences of phagocytic clearance of dying cells on neutrophil extracellular trap generation.The influence of sex and different segments of thoracic aorta on bioactive aortic substance (BAS) and prostacyclin (PGI2) synthesis.Oxidative stress elicits platelet/leukocyte inflammatory interactions via HMGB1: a candidate for microvessel injury in sytemic sclerosis.Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps.Anti-inflammatory action of apoptotic cells in patients with acute coronary syndromes.Anti-TNFα agents curb platelet activation in patients with rheumatoid arthritis.Early and transient release of leukocyte pentraxin 3 during acute myocardial infarction.Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation.Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemiaSelective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemiaCorrection: Early and Transient Release of Leukocyte Pentraxin 3 during Acute Myocardial InfarctionFormation of mixed platelet-PMN leukocyte aggregates in the platelet function analyzer (PFA-100) deviceParnaparin, a low-molecular-weight heparin, prevents P-selectindependent formation of platelet-leukocyte aggregates in human whole bloodInhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?Neutrophils and sepsisMore on: tissue factor in neutrophilsLeukocyte HMGB1 Is Required for Vessel Remodeling in Regenerating MusclesCirculating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosisStandardization in flow cytometry: correct sample handling as a priorityEffect of histamine on human lymphocyte aggregationIntraplatelet levels of vWF:Ag and fibrinogen in myeloproliferative disordersPlatelet function and intraplatelet von Willebrand factor antigen and fibrinogen in myelodysplastic syndromesHormonal regulation on bioactive aortic substance (BAS) productionPartial purification of a bioactive substance(s) from human veins independent of prostacyclin productionPurification and partial characterization of a bioactive substance from rat's vessel wall independent of prostacyclin productionLeukocyte and platelet activation in patients with giant cell arteritis and polymyalgia rheumatica: a clue to thromboembolic risks?Platelet microparticles sustain autophagy-associated activation of neutrophils in systemic sclerosisIncreased plasmatic NETs by-products in patients in severe obesityMacrophages Guard Endothelial Lineage by Hindering Endothelial-to-Mesenchymal Transition: Implications for the Pathogenesis of Systemic Sclerosis
P50
Q26749091-8D7ECE19-17FC-4F04-A585-369D55A7096BQ33317316-631E6163-2421-428D-B130-346A5F79D5B0Q33361592-003290ED-AFD2-4819-890B-5859E4BA4876Q34326162-2FE12B0F-1F49-4596-8E3D-07EE07EE651CQ34377832-33EC3456-AE0D-4D29-997B-A8F66F8DBAEAQ36867514-C71FBC42-141A-4815-B78A-D687B9A506F8Q37421806-6A678761-6E44-4F1B-B88B-3274C625465EQ37975846-219481A4-B201-4F9B-BD2C-970A530B2B78Q38194575-B39207A5-726F-4AEA-8A06-3BEE0844D767Q44698685-150844EA-AEDB-479C-9B89-3B848C81826EQ45856805-FE56FEFF-2AB8-42E8-8908-A6250A255733Q45868008-A194AEE7-62E5-4326-98FC-25CB7B4AF517Q51831766-4D8C75CF-4606-4247-8397-4C180B8EC229Q53195970-BFEB08B2-E488-40F0-90BB-EF82C801E31CQ53708193-DDCF4571-3188-425E-A1E3-634887C6A4B0Q54601092-E70BBBED-22BC-498C-9899-46A85BAFE8F0Q56942289-99AB8CF6-BA75-4A77-BA4F-F21FEA540F4FQ56942323-A4E5C490-3B5D-4CEC-B968-9F229E65EAD1Q56942353-C33FA76F-64A9-4645-BFBB-60E71E2A65C5Q58411862-D77CCDDC-B71A-4514-98BC-03E82CD8B38DQ58411869-FD43D3C7-91C4-479A-8F9E-3C20AD055266Q58411876-D77FF9DF-9C17-4A13-B8BB-C2C1DC056E4EQ58411881-9B42CD32-A9A8-4E51-B6A2-AD14BBB2F208Q58411890-947847AC-E88E-4CE9-9CF2-5BDFDFAA243FQ61779987-3B291900-28A8-4388-9106-FBD9200359D6Q61780011-E970B877-525C-4166-A251-2EDCB6468C6DQ61962995-3A01BCAA-D7D7-4372-B383-BEF29686371AQ67898832-174459F1-596C-4463-9F92-F9631EF28059Q68836517-D6E0E860-1EE2-485F-85A2-21B077ECB39CQ69174459-E6A6444C-C17E-479C-A390-1EBBA0DF4EDCQ69400773-DA14CE9F-BE56-471E-B1B8-2D0B4937D10EQ69538608-A147DFE2-DD4A-470A-86BA-FD58283EBC07Q70227919-B4BB4EB7-A0B1-4414-B991-A4197C3EC0B2Q84660956-69BFF878-5932-415D-99BB-2184E83C1D3FQ90474305-182DE9C8-02FC-4BF5-BABE-923CD31D1138Q90663326-89A8D197-4044-4DB6-89E2-B0DBDB84A5C7Q92282032-ECD2DE45-50D1-4592-9492-22ED00FA885E
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Norma Maugeri
@ast
Norma Maugeri
@en
Norma Maugeri
@es
Norma Maugeri
@nl
Norma Maugeri
@sl
type
label
Norma Maugeri
@ast
Norma Maugeri
@en
Norma Maugeri
@es
Norma Maugeri
@nl
Norma Maugeri
@sl
prefLabel
Norma Maugeri
@ast
Norma Maugeri
@en
Norma Maugeri
@es
Norma Maugeri
@nl
Norma Maugeri
@sl
P106
P1153
6603090955
P21
P31
P496
0000-0003-3931-0412